Publications in 2014 advanced our therapeutic armamentarium for bladder cancer. Molecular characterization might propel us into an era of targeted therapy, and immunotherapeutics might expand our options for patients with metastatic disease. We were also reminded that outcomes are inextricably linked to the quality of the transurethral resections we perform.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy
Oncogenesis Open Access 23 January 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Cancer Genome Atlas Research Network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315–322 (2014).
Wagle, N. et al. Activating mTOR mutations in a patient with an extraordinary response on a phase I trial of everolimus and pazopanib. Cancer Discov. 4, 546–553 (2014).
Sylvester, R. J. et al. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur. Urol. 49, 466–477; discussion 623–627 (2006).
James, A. C. & Gore, J. L. The costs of non-muscle invasive bladder cancer. Urol. Clin. North Am. 40, 261–269 (2013).
Solsona, E. et al. Sequential combination of mitomycin C plus bacillus Calmette-Guérin (BCG) is more effective but more toxic than BCG alone in patients with non-muscle-invasive bladder cancer in intermediate- and high-risk patients: final outcome of CUETO 93009, a randomized prospective trial. Eur. Urol. http://dx.doi.org/10.1016/j.eururo.2014.09.026.
Inman, B. A. et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109, 1499–1505 (2007).
Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558–562 (2014).
Mahoney, K. M. & Atkins, M. B. Prognostic and predictive markers for the new immunotherapies. Oncology (Williston Park) 28, 202335 (2014).
Gore, J. L. et al. Mortality increases when radical cystectomy is delayed more than 12 weeks: results from a Surveillance, Epidemiology, and End Results-Medicare analysis. Cancer 115, 988–996 (2009).
Chamie, K. et al. Quality of diagnostic staging in patients with bladder cancer: a process–outcomes link. Cancer http://dx.doi.org/10.1002/cncr.29071.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Lenis, A., Chamie, K. From the genomic frontier to immunotherapeutics. Nat Rev Urol 12, 74–76 (2015). https://doi.org/10.1038/nrurol.2014.369
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrurol.2014.369